You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/76840
Full metadata record
DC FieldValueLanguage
dc.contributor.authorForlenza, Orestes V.-
dc.contributor.authorDiniz, Breno S.-
dc.contributor.authorTeixeira, Antonio L.-
dc.contributor.authorStella, Florindo-
dc.contributor.authorGattaz, Wagner-
dc.date.accessioned2014-05-27T11:30:51Z-
dc.date.accessioned2016-10-25T18:54:57Z-
dc.date.available2014-05-27T11:30:51Z-
dc.date.available2016-10-25T18:54:57Z-
dc.date.issued2013-10-14-
dc.identifierhttp://dx.doi.org/10.1590/1516-4446-2012-3505-
dc.identifier.citationRevista Brasileira de Psiquiatria, v. 35, n. 3, p. 284-294, 2013.-
dc.identifier.issn1516-4446-
dc.identifier.urihttp://hdl.handle.net/11449/76840-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/76840-
dc.description.abstractTo present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings. © 2013 Associação Brasileira de Psiquiatria.en
dc.format.extent284-294-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectAlzheimer's disease-
dc.subjectAmyloid-β protein-
dc.subjectBiomarkers-
dc.subjectMild cognitive impairment-
dc.subjectNeuroimaging-
dc.subjectTau protein-
dc.titleMild cognitive impairment (part 2): Biological markers for diagnosis and prediction of dementia in Alzheimer's diseaseen
dc.typeoutro-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationLaboratory of Neuroscience (LIM-27) Department and Institute of Psychiatry School of Medicine, Universidade de São Paulo (USP), São Paulo, SP-
dc.description.affiliationDepartment of Mental Health School of Medicine Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG-
dc.description.affiliationNeuroimmunology Group Laboratory of Immunopharmacology Institute of Biological Sciences, UFMG, Belo Horizonte, MG-
dc.description.affiliationDepartment of Internal Medicine School of Medicine UFMG, Belo Horizonte, MG-
dc.description.affiliationBiosciences Institute Universidade Estadual Paulista (UNESP), Rio Claro, SP-
dc.description.affiliationUnespBiosciences Institute Universidade Estadual Paulista (UNESP), Rio Claro, SP-
dc.identifier.doi10.1590/1516-4446-2012-3505-
dc.identifier.scieloS1516-4446-2012-3505-
dc.identifier.wosWOS:000326034600015-
dc.rights.accessRightsAcesso aberto-
dc.identifier.file2-s2.0-84885119225.pdf-
dc.relation.ispartofRevista Brasileira de Psiquiatria-
dc.identifier.scopus2-s2.0-84885119225-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.